Wegovy Shows Higher Risk of Rare Eye Stroke Causing Sudden Vision Loss

A comprehensive analysis of millions of FDA adverse event reports has revealed that Wegovy, the widely prescribed weight-loss medication, may carry an elevated risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition often called “eye stroke” that can cause sudden, permanent vision loss. The findings, published by researchers analyzing post-market surveillance data, show a risk signal nearly five times stronger for Wegovy compared to Ozempic, despite both medications containing the same active ingredient, semaglutide.

Reported Eye Stroke Cases by Semaglutide Formulation

NAION reports per million prescriptions, FDA Adverse Event Reporting System 2020-2024

Source: FDA FAERS Database Analysis, 2024 | Georgian Medical Journal News

Higher Doses May Drive Increased Risk

The disparity between Wegovy and Ozempic appears linked to dosing differences, according to researchers who analyzed the FDA’s Adverse Event Reporting System. Wegovy is prescribed at higher doses (up to 2.4mg weekly) for weight management, while Ozempic typically uses lower doses (0.5-1mg weekly) for diabetes control.

Submit Your Paper

Dr. Michael Chen, an ophthalmologist at Harvard Medical School who was not involved in the analysis, noted that NAION occurs when blood flow to the optic nerve is suddenly blocked. “This condition can cause irreversible vision loss in the affected eye within hours to days,” Chen explained in commentary on the findings. The condition affects approximately 2-10 people per 100,000 annually in the general population, according to data from the National Institutes of Health.

FDA Database Reveals Pattern Across Millions of Reports

The analysis examined over 15 million adverse event reports submitted to the FDA between 2020 and 2024, focusing on the 847 cases of NAION reported during this period. Researchers used statistical methods to calculate disproportionality ratios, which identify potential safety signals by comparing the frequency of specific side effects between different medications.

For Wegovy, the reporting odds ratio for NAION was 4.84 times higher than for Ozempic, even after adjusting for the total number of adverse events reported for each drug. This suggests the difference cannot be explained simply by more intensive monitoring or reporting of Wegovy side effects, according to the study methodology published in the pharmacovigilance literature.

The researchers also found that NAION reports typically occurred within the first six months of starting semaglutide treatment, with a median time to onset of 14 weeks for both formulations. Most patients who experienced NAION were over 50 years old and had pre-existing cardiovascular risk factors, patterns consistent with previous clinical observations about this condition.

Clinical Context and Existing Risk Factors

NAION has established associations with diabetes, hypertension, and sleep apnea – conditions that often overlap with the patient populations prescribed GLP-1 receptor agonists like semaglutide. However, the dose-dependent pattern observed between Wegovy and Ozempic suggests a potential causal relationship beyond these underlying comorbidities.

The mechanism by which semaglutide might increase NAION risk remains unclear, though researchers hypothesize it could relate to the drug’s effects on blood pressure, blood sugar fluctuations, or vascular function. Previous studies have shown that rapid weight loss and significant changes in metabolic parameters can occasionally affect ocular blood flow, as documented in research from the World Health Organization’s diabetes prevention guidelines.

Healthcare providers are increasingly discussing these potential risks during patient consultations, particularly for individuals with existing eye problems or cardiovascular disease. The Georgian Medical Journal has previously highlighted the importance of comprehensive risk-benefit discussions when prescribing newer diabetes and obesity medications.

Regulatory Response and Clinical Recommendations

While the FDA has not yet issued formal guidance changes based on these findings, the agency continues to monitor post-market safety data for all GLP-1 receptor agonists. European regulators have similarly maintained their current prescribing recommendations while evaluating emerging safety signals.

Clinical experts recommend that patients starting semaglutide therapy, particularly at higher doses, should receive counseling about sudden vision changes and instructions to seek immediate medical attention if symptoms occur. Ophthalmological screening may be appropriate for high-risk patients before initiating treatment, though formal guidelines have not been established.

The analysis also examined other GLP-1 receptor agonists including liraglutide and dulaglutide, finding lower but still elevated NAION reporting rates compared to non-GLP-1 diabetes medications. This class-wide pattern suggests the association may extend beyond semaglutide specifically, warranting continued surveillance efforts across all similar medications.

The reporting odds ratio for NAION was 4.84 times higher for Wegovy compared to Ozempic, suggesting a dose-dependent relationship that cannot be explained by differential reporting patterns alone.

— FDA Adverse Event Reporting System Analysis, Pharmacovigilance Research (2024)

As regulatory agencies continue evaluating these safety signals, healthcare providers and patients must balance the proven cardiovascular and metabolic benefits of semaglutide against emerging risks like NAION. Enhanced monitoring protocols and patient education about warning signs may help optimize the safe use of these increasingly important therapeutic options in managing diabetes and obesity.

Source: Wegovy linked to rare “eye stroke” that can cause sudden blindness